Dynamic Blood Concentrations of Aβ1-40 and Aβ1-42 in Alzheimer's Disease

Yuan-Han Yang; Ling-Chun Huang; Sun-Wung Hsieh; Li-Ju Huang

doi:10.3389/fcell.2020.00768

Dynamic Blood Concentrations of Aβ_1-40 and Aβ_1-42 in Alzheimer's Disease

Front Cell Dev Biol. 2020 Aug 11:8:768. doi: 10.3389/fcell.2020.00768. eCollection 2020.

Authors

Yuan-Han Yang^{1

2

3

4

5}, Ling-Chun Huang^{1

2}, Sun-Wung Hsieh^{1

6}, Li-Ju Huang^{1

3}

Affiliations

¹ Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
² Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
³ Center of Teaching and Research, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁴ Department of and Master's Program in Neurology, Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁵ Neuroscience Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁶ Department of Neurology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Abstract

Amyloid-beta (Aβ) is produced by the cleavage of amyloid precursor proteins in the cell membrane by β-secretase and γ-secretase into a monomeric form with peptides of different lengths such as Aβ_1-40 or Aβ_1-42, which is then transformed into oligomeric and fibril forms and is considered to be one of the hallmarks of Alzheimer's disease (AD). The plasma concentrations of Aβ_1-40 and Aβ_1-42 are unstable after blood samples have been obtained. In order to examine the dynamic changes of plasma Aβ_1-42 and Aβ_1-40 in blood samples, we used fresh blood samples in ethylenediaminetetraacetic acid tubes from 32 clinically diagnosed AD patients. Each sample was subdivided into eight sub-samples, and levels of Aβ_1-40 and Aβ_1-42 were measured at 0 (baseline), 0.5, 1, 2, 3, 5, 8, and 24 h, respectively. All samples were incubated at 37°C before being measuring. The results showed that compared to baseline, 87.5 and 62.5% of the patients had higher plasma levels of Aβ_1-42 and Aβ_1-40 at 24 h, respectively. The patients with an increased amyloid level did not have a significantly different apo-lipoprotein E4 allele (APOE4) gene status for either Aβ_1-40 (p = 0.422) or Aβ_1-42 (p = 1.000). However, for plasma Aβ_1-42, the APOE4 carriers had a significantly lower level than the non-carriers at baseline [31.2 ± 6.5 (mean ± SD) ng/ml vs. 50.4 ± 47.7 ng/ml, p = 0.031] and 0.5 h (37.5 ± 7.6 ng/ml vs. 51.9 ± 30.8 ng/ml, p = 0.043). There were no significant differences between the APOE4 carriers and non-carriers in plasma Aβ_1-42 concentration at 1, 2, 3, 5, 8, and 24 h (p = 0.112, p = 0.086, p = 0.112, p = 0.263, p = 0.170 and p = 0.621, respectively). The Aβ_1-40 level was related to disease severity as assessed using the clinical dementia rating (CDR) scale. Patients with advanced stages of dementia (CDR = 1 and CDR = 2) had a significantly higher Aβ_1-40 level compared to those with very mild stage dementia (CDR = 0.5) at all time points (p < 0.05) except for 24 h (p = 0.059). Our findings illustrate the effects of APOE4 status on dynamic changes in plasma Aβ_1-40 and Aβ_1-42 levels, and significant associations between Aβ_1-40 level and disease severity. Further studies are needed to investigate the exact mechanisms of how APOE4 affects the dynamic changes in plasma Aβ_1-40 and Aβ_1-42, and the association between Aβ_1-40 and advanced dementia.

Keywords: APOE; Alzheimer’s disease; CDR; amyloid-beta-protein; dementia.